While Food and Drug Administration staff said the drug is effective, they focused on safety concerns in a review of dapagliflozin released Friday ahead of a Tuesday FDA advisory panel meeting in Silver Spring, Md. Bristol-Myers and AstraZeneca, which has its U.S. headquarters in Fairfax, have said they expect a final decision on approval by Oct. 28.
Saturday, July 16, 2011
AZ diabetes drug may cause cancer | The News Journal | delawareonline.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment